Impilo & Pelago Bioscience Partnership!

Stockholm, Sweden
16 August 2023

Impilo invests in Pelago Bioscience AB and enters a partnership to accelerate Pelago’s growth.

Founded in 2013, Pelago is a fast-growing drug discovery focused contract research organisation offering services based on the patented CEllular Thermal Shift Assay (CETSA®) technology. CETSA® provides unique value to customers in accelerating drug discovery projects given its ability to quantify how a drug compound binds to its intended target and perturb the biology in whole-cell physiological conditions.

This partnership is a great opportunity to expand Pelago’s outreach to new partners and customers to continue the mission to improve drug discovery and ultimately human health world-wide.

“Pelago has established itself as a unique and highly reliable technology and service provider in the discovery of novel therapeutics, with significant growth runway for the Company’s existing platform centered around its patented CETSA® technology for target engagement assessment. Impilo is excited to partner with the Founders and support the management team of Pelago in driving market penetration and a customer focused platform expansion with an attractive scope to broaden the service portfolio, organically as well as through M&A, and thus assist customers through several phases of the drug discovery process.”

Victor Steien


We are overly excited, and we look forward to a long lasting and rewarding partnership with Impilo.

Michael Dabrowski


“Impilo is the ideal partner for Pelago as we continue on our mission to enable better drug discovery for our customers. As a long-term and dedicated healthcare and life science investor, with vast experience from the pharma services sector, Impilo will contribute important competence for the next phase of our growth journey. Through the partnership we will be able to further invest and build our capacity and competence to accelerate business development initiatives and expand the applicability of our CETSA® technology for the benefit of our existing and new customers. We as Founders, together with the entire Pelago team, look forward to this next exciting phase in the development of the Company.”